Sapropterin Dihydrochloride has 8 known drug interactions based on U.S. FDA drug labeling data. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Levodopa, Methotrexate, Phenobarbital. Patients taking Sapropterin Dihydrochloride should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 8
- Major
- 1
- Moderate
- 7
Major (1)
- Sapropterin Dihydrochloride + Levodopa— Sapropterin may increase tyrosine availability, a levodopa precursor. Neurologic events reported post-marketing in patie…
Moderate (7)
- Sapropterin Dihydrochloride + Methotrexate— May decrease endogenous BH4 levels by inhibiting dihydrofolate reductase, potentially increasing phenylalanine levels.
- Sapropterin Dihydrochloride + Phenobarbital— May decrease endogenous BH4 levels by inhibiting dihydrofolate reductase, potentially increasing phenylalanine levels.
- Sapropterin Dihydrochloride + Sildenafil— Both sapropterin and PDE-5 inhibitors may induce vasorelaxation, potentially reducing blood pressure.
- Sapropterin Dihydrochloride + Tadalafil— Both sapropterin and PDE-5 inhibitors may induce vasorelaxation, potentially reducing blood pressure.
- Sapropterin Dihydrochloride + Trimethoprim— May decrease endogenous BH4 levels by inhibiting dihydrofolate reductase, potentially increasing phenylalanine levels.
- Sapropterin Dihydrochloride + Valproic Acid— May decrease endogenous BH4 levels by inhibiting dihydrofolate reductase, potentially increasing phenylalanine levels.
- Sapropterin Dihydrochloride + Vardenafil— Both sapropterin and PDE-5 inhibitors may induce vasorelaxation, potentially reducing blood pressure.